Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Metoclopramide is primarily a dopamine receptor antagonist, with 5HT 3 receptor antagonist and 5HT 4 receptor agonist activity, and used as an antiemetic and gastroprokinetic since almost 50 years. Regulatory authorities issued restrictions and recommendations regarding long‐term use of the drug at oral doses exceeding 10 mg 3‐4 times daily because of the risk for development of tardive dyskinesia. The aim of our study was to review mechanism(s) of action and pharmacokinetic‐pharmacodynamic properties of metoclopramide, as well as the risk of metoclopramide‐induced tardive dyskinesia, factors that may change drug exposure in humans, and to summarize the clinical context for appropriate use of the drug. Methods: A PubMed, Google Scholar, and Cross Reference search was done using the key words and combined searches: drug‐drug interaction, gastroparesis, metoclopramide, natural history, pharmacokinetics, pharmacodynamics, drug‐drug interaction, outcome, risk factors, tardive dyskinesia. Key results: Data show that the risk of tardive dyskinesia from metoclopramide is low, in the range of 0.1% per 1000 patient years. This is far below a previously estimated 1%‐10% risk suggested in treatment guidelines by regulatory authorities. High‐risk groups are elderly females, diabetics, patients with liver or kidney failure, and patients with concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications. Conclusions & Inferences: The risk of tardive dyskinesia due to metoclopramide is far below approximated numbers in treatment guidelines. This risk and the influence of known risk factors should be considered when starting a course of metoclopramide for treatment of gastroparesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Self-citationThe physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Parkman, H. P., Hasler, W. L., & Fisher, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.055 · Cited by 738
Jung, H., Choung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R., Szarka, L. A., Mullan, B., & Talley, N. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.047 · Cited by 571
Abell, T. L., Bernstein, V. K., Cutts, T., Farrugia, G., Forster, J., Hasler, W. L., Mccallum, R. W., Olden, K. W., Parkman, H. P., Parrish, C. R., et al. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00760.x · Cited by 361
Review article: metoclopramide and tardive dyskinesia
RAO, A. S., & CAMILLERI, M. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04189.x · Cited by 316
Domperidone: Review of Pharmacology and Clinical Applications in Gastroenterology
Reddymasu, S. C., Soykan, I., & McCallum, R. W. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01255.x · Cited by 304
Hyett, B., Martinez, F. J., Gill, B. M., Mehra, S., Lembo, A., Kelly, C. P., & Leffler, D. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.055 · Cited by 158
Cited by
ACG Clinical Guideline: Gastroparesis
Camilleri, M., Kuo, B., Nguyen, L., Vaughn, V. M., Petrey, J., Greer, K., Yadlapati, R., & Abell, T. L. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001874 · Cited by 332
“The most comprehensive assessment (71) showed that the risk of tardive dyskinesia frommetoclopramide is in the range of 0.”
BackgroundCamilleri, M., & Sanders, K. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.10.028 · Cited by 151
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
“1% per 1000 patient-years with metoclopramide [71].”
Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis
Ingrosso, M. R., Camilleri, M., Tack, J., Ianiro, G., Black, C. J., & Ford, A. C. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.12.014 · Cited by 53
Enteric neuropathy in diabetes: Implications for gastrointestinal function
Abdalla, M. M. I. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i22.2852 · Cited by 45
Metadata
- Authors
- Al‐Saffar, A., Lennernäs, H., & Hellström, P. M.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2019-05-02
- Volume
- 31
- Issue
- 11
- Pages
- e13617-e13617
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W2942690310
- Cited by
- 97
- References
- 8
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. https://app.cochat.ai/papers/10.1111/nmo.13617
- The paper
- Al‐Saffar, A., Lennernäs, H., & Hellström, P. M. (2019). Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.13617
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.